These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 19748318)

  • 1. A simple in vitro PK/PD model system to determine time-kill curves of drugs against Mycobacteria.
    Budha NR; Lee RB; Hurdle JG; Lee RE; Meibohm B
    Tuberculosis (Edinb); 2009 Sep; 89(5):378-85. PubMed ID: 19748318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New concept and a theoretical consideration of the mechanism-based pharmacokinetics/ pharmacodynamics (PK/PD) modeling for antimicrobial agents.
    Sato N; Suzuki H; Hayashi H; Shibasaki S; Sugano T; Maebashi K; Kurosawa T; Shiomi M; Ogata H
    Jpn J Antibiot; 2008 Oct; 61(5):314-38. PubMed ID: 19260351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of inhA, but not kasA, confers resistance to isoniazid and ethionamide in Mycobacterium smegmatis, M. bovis BCG and M. tuberculosis.
    Larsen MH; Vilchèze C; Kremer L; Besra GS; Parsons L; Salfinger M; Heifets L; Hazbon MH; Alland D; Sacchettini JC; Jacobs WR
    Mol Microbiol; 2002 Oct; 46(2):453-66. PubMed ID: 12406221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Mycobacterium tuberculosis iniA gene is essential for activity of an efflux pump that confers drug tolerance to both isoniazid and ethambutol.
    Colangeli R; Helb D; Sridharan S; Sun J; Varma-Basil M; Hazbón MH; Harbacheuski R; Megjugorac NJ; Jacobs WR; Holzenburg A; Sacchettini JC; Alland D
    Mol Microbiol; 2005 Mar; 55(6):1829-40. PubMed ID: 15752203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo efficiency of targeted norfloxacin against persistent, isoniazid-insensitive, Mycobacterium bovis BCG present in the physiologically hypoxic mouse liver.
    Balazuc AM; Lagranderie M; Chavarot P; Pescher P; Roseeuw E; Schacht E; Domurado D; Marchal G
    Microbes Infect; 2005 Jun; 7(7-8):969-75. PubMed ID: 15994108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations.
    Gumbo T; Louie A; Liu W; Brown D; Ambrose PG; Bhavnani SM; Drusano GL
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2329-36. PubMed ID: 17438043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mathematical modeling and systems pharmacology of tuberculosis: Isoniazid as a case study.
    Lalande L; Bourguignon L; Maire P; Goutelle S
    J Theor Biol; 2016 Jun; 399():43-52. PubMed ID: 27059890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Rifampicin-resistant Mycobacterium bovis BCG strain isolated from an infant with NEMO mutation].
    Çavuşoğlu C; Edeer Karaca N; Azarsız E; Ulusoy E; Kütükçüler N
    Mikrobiyol Bul; 2015 Apr; 49(2):272-7. PubMed ID: 26167828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamic time-kill curve characterization of spectinamide antibiotics 1445 and 1599 for the treatment of tuberculosis.
    Vaddady PK; Trivedi A; Rathi C; Madhura DB; Liu J; Lee RE; Meibohm B
    Eur J Pharm Sci; 2019 Jan; 127():233-239. PubMed ID: 30419293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contribution of efflux activity to isoniazid resistance in the Mycobacterium tuberculosis complex.
    Rodrigues L; Machado D; Couto I; Amaral L; Viveiros M
    Infect Genet Evol; 2012 Jun; 12(4):695-700. PubMed ID: 21871582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of in vitro synergy between vertilmicin and ceftazidime against Pseudomonas aeruginosa using a semi-mechanistic pharmacokinetic/pharmacodynamic model.
    Zhuang L; Sy SK; Xia H; Singh RP; Mulder MB; Liu C; Derendorf H
    Int J Antimicrob Agents; 2015 Feb; 45(2):151-60. PubMed ID: 25465523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro pharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TB.
    Vaddady PK; Lee RE; Meibohm B
    Future Med Chem; 2010 Aug; 2(8):1355-69. PubMed ID: 21359155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid mycobacteria drug susceptibility testing using Gel Microdrop (GMD) Growth Assay and flow cytometry.
    Akselband Y; Cabral C; Shapiro DS; McGrath P
    J Microbiol Methods; 2005 Aug; 62(2):181-97. PubMed ID: 16009276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential Sensitivity of Mycobacteria to Isoniazid Is Related to Differences in KatG-Mediated Enzymatic Activation of the Drug.
    Reingewertz TH; Meyer T; McIntosh F; Sullivan J; Meir M; Chang YF; Behr MA; Barkan D
    Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31767723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combatting the Rising Tide of Antimicrobial Resistance: Pharmacokinetic/Pharmacodynamic Dosing Strategies for Maximal Precision.
    Chua HC; Tse A; Smith NM; Mergenhagen KA; Cha R; Tsuji BT
    Int J Antimicrob Agents; 2021 Mar; 57(3):106269. PubMed ID: 33358761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of inhA and katG on isoniazid resistance and virulence of Mycobacterium bovis.
    Wilson TM; de Lisle GW; Collins DM
    Mol Microbiol; 1995 Mar; 15(6):1009-15. PubMed ID: 7623658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pharmacokinetic/pharmacodynamic model developed for the effect of colistin on Pseudomonas aeruginosa in vitro with evaluation of population pharmacokinetic variability on simulated bacterial killing.
    Mohamed AF; Cars O; Friberg LE
    J Antimicrob Chemother; 2014 May; 69(5):1350-61. PubMed ID: 24474432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isoniazid Resistance and Dosage as Treatment for Patients with Tuberculosis.
    Nagel S; Streicher EM; Klopper M; Warren RM; Van Helden PD
    Curr Drug Metab; 2017; 18(11):1030-1039. PubMed ID: 29086682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic-pharmacodynamic modeling and simulation for in vivo bactericidal effect in murine infection model.
    Katsube T; Yamano Y; Yano Y
    J Pharm Sci; 2008 Apr; 97(4):1606-14. PubMed ID: 17705288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative proteomics reveals novel insights into isoniazid susceptibility in mycobacteria mediated by a universal stress protein.
    Hu X; Li X; Huang L; Chan J; Chen Y; Deng H; Mi K
    J Proteome Res; 2015 Mar; 14(3):1445-54. PubMed ID: 25664397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.